Seeking Alpha

EXOSOME DIAGNOSTICS RELEASES INTERIM RESULTS FROM CLINICAL STUDY OF PROSTATE CANCER RISK TEST

Halfway through 5-year study, ExoDx Prostate Test offers more accurate stratification of high- and low-risk patients compared to standard of care MINNEAPOLIS, May 18, 2023 /PRNewswire/ -- Bio-Techne ...
CNN

Bio-Techne's Exosome Diagnostics Launches ExoDx Prostate At-Home Collection Kit

MINNEAPOLIS, April 15, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) announced today that Exosome Diagnostics, a Bio-Techne brand, is launching an ExoDx™ Prostate Test At-Home Collection ...
Nasdaq

Bio-Techne Announces Exosome Diagnostics Divestiture

MINNEAPOLIS, Aug. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced an agreement where Mdxhealth SA will acquire its Exosome Diagnostics Inc. business, including the ExoDx ...
Seeking Alpha

Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne

IRVINE, CA, and HERSTAL, BELGIUM – August 5, 2025 (GlobeNewswire) – MDxHealth SA (MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced preliminary financial ...
Business Insider

Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer

Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer IRVINE, CA – January XX, 2026 (GlobeNewswire) ...
Insider Monkey

MDxHealth Completes Bio Techne ExoDx Acquisition to Bolster Precision Diagnostics

MDxHealth SA (NASDAQ:MDXH) is among the best fundamentally strong penny stocks to buy right now. On September 15, 2025, MDxHealth SA (NASDAQ:MDXH) announced the completion of its acquisition of ...